NCT06161974

Study of Olutasidenib and Temozolomide in HGG

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2025-02-01Est. Completion: 2029-06

Enrollment target: 60 participants

Locations

Children's Hospital Colorado, Aurora, Colorado, United States
Children's National Medical Center, Washington D.C., District of Columbia, United States
University of Miami Hospital and Clinics, Miami, Florida, United States
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Susan Chi, Boston, Massachusetts, United States
Duke University Health System, Durham, North Carolina, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Nationwide Children's Hospital, Columbus, Ohio, United States
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Texas Children's Hospital, Houston, Texas, United States
Seattle Children's Hospital, Seattle, Washington, United States
Sydney Children's Hospital, Randwick, New South Wales, Australia
Queensland Children's Hospital, South Brisbane, Queensland, Australia
Perth Children's Hospital, Perth, Western Australia, Australia
The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada

Other microbiome trials you might be interested in

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent GlioblastomaPhase 1Recruiting

Recurrent GlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeRelapsed CancerRecurrent TumorGlioblastoma MultiformeRecurring GlioblastomaBrain and Central Nervous System TumorsGliomaGlioblastomasGrade IV AstrocytomaGBMRecurrent Glioma (Glioblastoma Multiforme)High Grade GliomaGlioma, MalignantBrain Cancer

Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. B…

Bethesda, United StatesEst. completion Dec 31, 2030

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.